The Incidence and Treatment Response of Double Expression of MYC and BCL2 in Patients with Diffuse Large B-Cell Lymphoma: A Systematic Review and Meta-Analysis

• Published in: Cancers Vol. 13; no. 13; p. 3369
• Main Authors: Hwang, Jisun, Suh, Chonghyun, Kim, Kyungwon, Kim, Hosung, Kim, Austin I, Craig, Jeffrey W, Chen, Ke Xun, Roberson, Joel, Guenette, Jeffrey P, Huang, Raymond Y
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 05.07.2021; MDPI
• Subjects: Age; B-cell lymphoma; Biomarkers; Chemotherapy; Cyclophosphamide; Doxorubicin; Gene expression; immunohistochemistry; Kinases; Lymphocytes B; Lymphoma; Meta-analysis; Mutation; Myc protein; Patients; Prednisone; Protein expression; Proteins; Remission; Rituximab; Systematic Review; Tumors; Vincristine; meta-analysis; immunohistochemistry; systematic review; lymphoma
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers13133369

MYC/BCL2 protein co-expression (i.e., double expressor) has been shown to be a negative predictor of outcome in diffuse large B-cell lymphoma (DLBCL). We aimed to establish the incidence of double expressor status in patients with de novo DLBCL and identify the predictive value of this biomarker on treatment response through systematic review and meta-analysis. PubMed and Embase were searched for studies published through December 2019 that reported proportions of double expressor DLBCL. The pooled proportions of MYC and BCL2 expression, both alone and in combination, were computed using the inverse variance method for calculating weights and by the DerSimonian-Laird method. The pooled odds ratios (ORs) of complete remission (CR) rate were calculated, and meta-regression analysis was conducted to explore heterogeneity. Forty-one studies (7054 patients) were included. The pooled incidence of double expressor status in DLBCL was 23% (95% confidence interval [CI], 20-26%), with an adjusted estimate of 31% (95% CI, 27-36%). Neither MYC/BCL2 protein cutoff values, race, mean, or median age of included patients, or overall study quality was a significant factor of heterogeneity ( ≥ 0.20). Cases without double expressor status demonstrated a higher probability of CR to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone treatment (OR, 2.69; 95% CI, 1.55-4.67). Our results reaffirm the predictive power of this important biomarker.